{{Refimprove|date=February 2010}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 460033773
| IUPAC_name = (''Z'')-3-(2-chlorothioxanthen-9-ylidene)-''N'',''N''-dimethyl-propan-1-amine
| image = Chlorprothixene structure.svg
| width = 200px
| image2 = Chlorprothixene3Dan.gif
| width2 = 180px

<!--Clinical data-->
| tradename = Truxal, others
| Drugs.com = {{drugs.com|CONS|chlorprothixene}}
| pregnancy_category = 
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]], [[intramuscular injection]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = Hepatic
| elimination_half-life = 8–12 hours
| excretion = Feces, urine

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 113-59-7
| ATC_prefix = N05
| ATC_suffix = AF03
| PubChem = 667467
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01239
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 580849
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9S7OD60EWP
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00790
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 50931
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 908

<!--Chemical data-->
| C=18 | H=18 | Cl=1 | N=1 | S=1
| molecular_weight = 315.861 g/mol
| SMILES = Clc2cc1C(\c3c(Sc1cc2)cccc3)=C/CCN(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WSPOMRSOLSGNFJ-AUWJEWJLSA-N
}}

'''Chlorprothixene''', sold under the brand name '''Truxal''' among others, is a [[typical antipsychotic]] of the [[thioxanthene]] group.

==Medical uses==
Chlorprothixene's principal indications are the treatment of [[psychotic disorder]]s (e.g. [[schizophrenia]]) and of acute [[mania]] occurring as part of [[bipolar disorder]]s.

Other uses are pre- and postoperative states with anxiety and insomnia, severe nausea / emesis (in hospitalized patients), the amelioration of anxiety and agitation due to use of [[selective serotonin reuptake inhibitor]]s for [[clinical depression|depression]] and, off-label, the amelioration of alcohol and opioid withdrawal. It may also be used cautiously to treat nonpsychotic irritability, aggression, and insomnia in pediatric patients.

An intrinsic [[antidepressant]] effect of chlorprothixene has been discussed, but not proven yet. Likewise, it is unclear, if chlorprothixene has genuine (intrinsic) [[analgesic]] effects. However, chlorprothixene can be used as comedication in severe chronic pain. Also, like most antipsychotics, chlorprothixene has [[antiemetic]] effects.

==Side effects==
Chlorprothixene has a strong sedative activity with a high incidence of [[anticholinergic]] side effects. The types of side effects encountered (dry mouth, massive [[hypotension]] and [[tachycardia]], [[hyperhidrosis]], substantial weight gain etc.) normally do not allow a full effective dose for the remission of psychotic disorders to be given. So cotreatment with another, more potent, antipsychotic agent is needed.

Chlorprothixene is structurally related to [[chlorpromazine]], with which it shares, in principle, all side effects. Allergic side effects and liver damage seem to appear with an appreciable lower frequency. The elderly are particularly sensitive to anticholinergic side effects of chlorprothixene (precipitation of narrow angle [[glaucoma]], severe obstipation, difficulties in urinating, confusional and delirant states). In patients >60 years the doses should be particularly low.

Early and late [[Extrapyramidal symptoms|extrapyramidal side effects]] may occur but have been noted with a low frequency (one study with a great number of participants has delivered a total number of only 1%).

==Overdose==
Overdose symptoms can be confusion, hypotension, and tachycardia, and several fatalities have been reported with concentrations in postmortem blood ranging from 0.1 to 7.0&nbsp;mg/L compared to non-toxic levels in postmortem blood which can extend to 0.4&nbsp;mg/kg.<ref name="Skov 2015 41-44">{{cite journal | vauthors = Skov L, Johansen SS, Linnet K | title = Postmortem Femoral Blood Reference Concentrations of Aripiprazole, Chlorprothixene, and Quetiapine | journal = Journal of Analytical Toxicology | volume = 39 | issue = 1 | pages = 41–44 | date = Jan 2015 | doi = 10.1093/jat/bku121 | pmid=25342720}}</ref>

==Interactions==
Chlorprothixene may increase the plasma-level of concomitantly given [[lithium]]. In order to avoid lithium intoxication, lithium plasma levels should be monitored closely.

If chlorprothixene is given concomitantly with [[opioid]]s, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side effects of opioids considerably.

Avoid the concomitant use of chlorprothixene and [[tramadol]] (Ultram). Seizures may be encountered with this combination.

Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with [[benzodiazepine]]s or [[barbiturate]]s. Choose particular low doses of these drugs.

Exert particular caution in combining chlorprothixene with other anticholinergic drugs ([[tricyclic antidepressant]]s and [[antiparkinsonian]] agents): Particularly the elderly may develop delirium, high fever, severe [[obstipation]], even [[ileus]] and glaucoma .

==Pharmacology==

===Pharmacodynamics===
{| class="wikitable floatright" style="font-size:small;"
|+ Chlorprothixene<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | format = HTML | accessdate = 14 August 2017 | url = https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=chlorprothixene&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site !! K<sub>i</sub> (nM) !! Species !! Ref
|-
| {{abbrlink|SERT|Serotonin transporter}} || 110 || {{abbr|ND|No data}} || <ref name="pmid16082416">{{cite journal | vauthors = Silvestre JS, Prous J | title = Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes | journal = Methods Find Exp Clin Pharmacol | volume = 27 | issue = 5 | pages = 289–304 | year = 2005 | pmid = 16082416 | doi = 10.1358/mf.2005.27.5.908643 | url = }}</ref>
|-
| '''{{abbrlink|NET|Norepinephrine transporter}}''' || '''21–532''' || '''Human''' || <ref name="pmid16082416" /><ref name="pmid17379857">{{cite journal | vauthors = Haunsø A, Buchanan D | title = Pharmacological characterization of a fluorescent uptake assay for the noradrenaline transporter | journal = J Biomol Screen | volume = 12 | issue = 3 | pages = 378–84 | year = 2007 | pmid = 17379857 | doi = 10.1177/1087057107299524 | url = }}</ref>
|-
| {{abbrlink|DAT|Dopamine transporter}} || 1,699 || {{abbr|ND|No data}} || <ref name="pmid16082416" />
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || 138–230 || Human || <ref name="pmid2891550">{{cite journal | vauthors = Wander TJ, Nelson A, Okazaki H, Richelson E | title = Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro | journal = Eur. J. Pharmacol. | volume = 143 | issue = 2 | pages = 279–82 | year = 1987 | pmid = 2891550 | doi = | url = }}</ref><ref name="pmid16082416" />
|-
| '''[[5-HT2A receptor|5-HT<sub>2A</sub>]]''' || '''0.30–0.43''' || '''Human''' || <ref name="pmid2891550" /><ref name="pmid16082416" />
|-
| [[5-HT2B receptor|5-HT<sub>2B</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| '''[[5-HT2C receptor|5-HT<sub>2C</sub>]]''' || '''4.5''' || '''{{abbr|ND|No data}}''' || <ref name="pmid16082416" />
|-
| [[5-HT3 receptor|5-HT<sub>3</sub>]] || 398 || {{abbr|ND|No data}} || <ref name="pmid16082416" />
|-
| '''[[5-HT6 receptor|5-HT<sub>6</sub>]]''' || '''3.0–3.2''' || '''Rat''' || <ref name="pmid16082416" /><ref name="pmid7908055">{{cite journal | vauthors = Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR | title = Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors | journal = J. Pharmacol. Exp. Ther. | volume = 268 | issue = 3 | pages = 1403–10 | year = 1994 | pmid = 7908055 | doi = | url = }}</ref><ref name="pmid10821800">{{cite journal | vauthors = Glusa E, Pertz HH | title = Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors | journal = Br. J. Pharmacol. | volume = 130 | issue = 3 | pages = 692–8 | year = 2000 | pmid = 10821800 | pmc = 1572101 | doi = 10.1038/sj.bjp.0703341 | url = }}</ref>
|-
| '''[[5-HT7 receptor|5-HT<sub>7</sub>]]''' || '''5.0–5.6''' || '''Rat''' || <ref name="pmid16082416" /><ref name="pmid7908055" /><ref name="pmid10821800" />
|-
| '''[[Alpha-1 adrenergic receptor|α<sub>1</sub>]]''' || '''1.0''' || '''{{abbr|ND|No data}}''' || <ref name="pmid16082416" />
|-
| [[Alpha-2 adrenergic receptor|α<sub>2</sub>]] || 186 || {{abbr|ND|No data}} || <ref name="pmid16082416" />
|-
| [[Beta-adrenergic receptor|β]] || >10,000 || Mammal || <ref name="pmid8699">{{cite journal | vauthors = Bylund DB, Snyder SH | title = Beta adrenergic receptor binding in membrane preparations from mammalian brain | journal = Mol. Pharmacol. | volume = 12 | issue = 4 | pages = 568–80 | year = 1976 | pmid = 8699 | doi = | url = }}</ref>
|-
| '''[[Dopamine D1 receptor|D<sub>1</sub>]]''' || '''12–18''' || '''Human''' || <ref name="pmid19091563">{{cite journal | vauthors = von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H | title = Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics | journal = Bioorg. Med. Chem. Lett. | volume = 19 | issue = 2 | pages = 538–42 | year = 2009 | pmid = 19091563 | doi = 10.1016/j.bmcl.2008.09.012 | url = }}</ref><ref name="pmid16082416" />
|-
| '''[[Dopamine D2 receptor|D<sub>2</sub>]]''' || '''3.0–5.6''' || '''Human''' || <ref name="pmid19091563" /><ref name="pmid9577836">{{cite journal | vauthors = Seeman P, Tallerico T | title = Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors | journal = Mol. Psychiatry | volume = 3 | issue = 2 | pages = 123–34 | year = 1998 | pmid = 9577836 | doi = | url = }}</ref><ref name="pmid16082416" />
|-
| '''[[Dopamine D3 receptor|D<sub>3</sub>]]''' || '''1.9–4.6''' || '''Human''' || <ref name="pmid16082416" /><ref name="pmid19091563" />
|-
| '''[[Dopamine D4 receptor|D<sub>4</sub>]]''' || '''0.65''' || '''Human''' || <ref name="pmid9577836" /><ref name="pmid16082416" />
|-
| '''[[Dopamine D5 receptor|D<sub>5</sub>]]''' || '''9.0''' || '''Human''' || <ref name="pmid19091563" />
|-
| '''[[Histamine H1 receptor|H<sub>1</sub>]]''' || '''0.89–3.8''' || '''Human''' || <ref name="pmid16082416" /><ref name="pmid19091563" />
|-
| [[Histamine H3 receptor|H<sub>3</sub>]] || >1,000 || Human || <ref name="pmid19091563" />
|-
| '''{{abbrlink|mACh|Muscarinic acetylcholine receptor}}''' || '''41''' || '''{{abbr|ND|No data}}''' || <ref name="pmid16082416" />
|-
| &nbsp;&nbsp;'''[[Muscarinic acetylcholine receptor M1|M<sub>1</sub>]]''' || '''11–26''' || '''Human''' || <ref name="pmid1346637">{{cite journal | vauthors = Bolden C, Cusack B, Richelson E | title = Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells | journal = J. Pharmacol. Exp. Ther. | volume = 260 | issue = 2 | pages = 576–80 | year = 1992 | pmid = 1346637 | doi = | url = }}</ref><ref name="pmid16082416" />
|-
| &nbsp;&nbsp;'''[[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]]''' || '''28–79''' || '''Human''' || <ref name="pmid1346637" /><ref name="pmid16082416" />
|-
| &nbsp;&nbsp;'''[[Muscarinic acetylcholine receptor M3|M<sub>3</sub>]]''' || '''22''' || '''Human''' || <ref name="pmid1346637" /><ref name="pmid16082416" />
|-
| &nbsp;&nbsp;'''[[Muscarinic acetylcholine receptor M4|M<sub>4</sub>]]''' || '''18''' || '''Human''' || <ref name="pmid1346637" />
|-
| &nbsp;&nbsp;'''[[Muscarinic acetylcholine receptor M5|M<sub>5</sub>]]''' || '''25''' || '''Human''' || <ref name="pmid1346637" />
|-
| [[Sigma receptor|σ]] || 603 || {{abbr|ND|No data}} || <ref name="pmid16082416" />
|- class="sortbottom"
| colspan="4" style="width: 1px;" | Values are K<sub>i</sub> (nM). The smaller the value, the more strongly the drug binds to the site.
|}

Chlorprothixene is an [[receptor antagonist|antagonist]] of the following [[receptor (biochemistry)|receptor]]s:

* [[5-HT2 receptor|5-HT<sub>2</sub>]]: antipsychotic effects, anxiolysis, weight gain
* [[D1 receptor|D<sub>1</sub>]], [[D2 receptor|D<sub>2</sub>]], [[D3 receptor|D<sub>3</sub>]]: antipsychotic effects, sedation, extrapyramidal side effects, prolactin increase, depression, apathy/anhedonia, weight gain
* [[H1 receptor|H<sub>1</sub>]]: sedation, weight gain
* [[Muscarinic acetylcholine receptor]]s: anticholinergic effects, inhibition of extrapyramidal side effects
* [[Alpha-1 adrenergic receptor|α<sub>1</sub>-Adrenergic]]: hypotension, tachycardia

Because of its potent serotonin 5-HT<sub>2A</sub> and muscarinic acetylcholine receptor antagonism, chlorprothixene causes relatively mild [[extrapyramidal symptom]]s.<ref name="Csernansky2012">{{cite book|author=John G. Csernansky|title=Antipsychotics|url=https://books.google.com/books?id=hiz6CAAAQBAJ&pg=PA360|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-61007-3|pages=360–}}</ref> This is in contrast to most other typical antipsychotics.<ref name="Csernansky2012" /> For this reason, chlorprothixene has sometimes been described instead as an [[atypical antipsychotic]].<ref name="Csernansky2012" />

Chlorprothixene has also been found to act as [[FIASMA]] (functional inhibitor of [[Sphingomyelin phosphodiesterase|acid sphingomyelinase]]).<ref name="pmid18504571">{{cite journal |vauthors=Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Mühle C, Terfloth L, Groemer T, Spitzer G, Liedl K, Gulbins E, Tripal P|title=Identification of novel functional inhibitors of acid sphingomyelinase|journal=PLoS ONE|volume=6|issue=8|pages=e23852|year=2011|doi=10.1371/journal.pone.0023852|pmid=21909365|pmc=3166082}}</ref>

===Pharmacokinetics===
One metabolite of chlorprothixene is ''N''-desmethylchlorprothixene.

[[File:Desmethylchlorprothixene.svg|thumb|center|215px|Structure of ''N''-desmethylchlorprothixene]]

==Chemistry==

===Synthesis===
Chlorprothixene (2-chloro-9[(1-dimethylamino)-3-propyliden]thioxanthene) is made starting from [[2-chlorothioxanthone]]. 2-Chlorothioxantone, in turn, is prepared from 2-mercaptobenzoic acid ('''1'''), the reaction of which with 1-bromo-4-chlorobenzene ('''2''') forms 2-(4-chlorophenylthio)benzoic acid '''5''', which upon reaction with [[phosphorus pentachloride]] transforms into acid chloride ('''6'''), and further undergoes intramolecular cyclization with the use of [[aluminum chloride]] to give 2-chlorthioxantone ('''6''').<ref>H. Spiegelberg, K. Doeben, {{Cite patent|DE|1044103}} (1957).</ref>

An alternative way of making 2-chlorthioxantone ('''7''') is by making 2-(4-chlorophenylthio)benzoic acid ('''5''') by reacting 2-iodobenzoic acid ('''3''') with 4-chlorothiophenol ('''4''').<ref>E.L. Engelhardt, J.M. Sprague, {{US Patent|2951082}} (1960).</ref>

[[File:2-Chlorothioxantone synthesis.svg|thumb|center|700px|2-Chlorothioxantone synthesis: {{Cite patent|DE|1044103}} {{US patent|2951082}}]]

The resulting 2-chlorothioxantone is reacted as a [[carbonyl]] component with either 3-dimethylaminopropylmagnesiumbromide (see Engelhardt above), or with allylmagnesiumbromide, giving the corresponding tertiary alcohols '''8''', and '''9'''.

[[File:Chlorprothixene synth.svg|400px|center|thumb|Chlorprothixene synthesis:{{US Patent|3116291}} {{Cite patent|DE|1168446}} {{Cite patent|DE|1418517}}]]

Dehydration of the tertiary ('''8''') is accomplished by [[acylation]] of the tertiary hydroxyl group using [[acetyl chloride]] and the subsequent [[pyrolysis]] of the formed acetate, which leads to the desired chlorprothixene. In the second case, dehydration of the tertiary alcohol ('''9''') is accomplished by chlorination of the tertiary alcohol group by [[thionyl chloride]], forming the diene 2-chloro-9-(3-propen-1-iliden)thioxanthene ('''10'''), the addition to which of [[dimethylamine]] at high temperature forms the desired chlorprothixene ('''11''').

==History==
Chlorprothixene was the first of the [[thioxanthene]] antipsychotics to be synthesized.<ref name="isbn0-674-03958-0">{{cite book | author = Healy, David | title = The antidepressant era | publisher = Harvard University Press | location = Cambridge | year = 1997 | page = 182 | isbn = 0-674-03958-0 | oclc = | doi = | url = https://books.google.com/books?id=6lpHd_P4VOsC&lpg=RA2-PA182&dq=chlorprothixene%20antidepressant&as_brr=3&pg=RA2-PA182#v=onepage&q=chlorprothixene%20antidepressant&f=false}}</ref> It was introduced in 1959 by [[Lundbeck]].<ref name="isbn0-471-89980-1">{{cite book | author = Sneader, Walter | title = Drug discovery: a history | publisher = Wiley | location = New York | year = 2005 | page = 410 | isbn = 0-471-89980-1 | oclc = | doi = | url = https://books.google.com/books?id=Cb6BOkj9fK4C&lpg=PA410&dq=chlorprothixene%20introduced%201958&pg=PA410#v=onepage&q=chlorprothixene%20introduced%201958&f=false}}</ref>

[[Lometraline]], [[tametraline]], and [[sertraline]] were reportedly derived via [[structural modification]] of chlorprothixene.{{Citation needed|date=August 2017}}

==Society and culture==

===Brand names===
Chlorprothixene is sold mainly under the brand name Truxal.<ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA224|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=224–}}</ref><ref name="Drugs.com">https://www.drugs.com/international/chlorprothixene.html</ref>

===Availability===
Chlorprothixene is widely available throughout [[Europe]] and elsewhere in the world.<ref name="IndexNominum2000" /><ref name="Drugs.com" /> The drug was previously available in the [[United States]] under the brand name Taractan, but this formulation has since been discontinued and the drug is no longer available in this country.<ref name="Drugs@FDA">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012486</ref>

==References==
{{Reflist|30em}}

{{Antipsychotics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}
{{Authority control}}

[[Category:5-HT2A antagonists]]
[[Category:5-HT6 antagonists]]
[[Category:5-HT7 antagonists]]
[[Category:Alpha-1 blockers]]
[[Category:Amines]]
[[Category:Antihistamines]]
[[Category:Chloroarenes]]
[[Category:D1 antagonists]]
[[Category:D2 antagonists]]
[[Category:D3 antagonists]]
[[Category:D4 antagonists]]
[[Category:D5 antagonists]]
[[Category:H1 receptor antagonists]]
[[Category:Muscarinic antagonists]]
[[Category:Thioxanthene antipsychotics]]